Researchers are studying the effectiveness of a multimodal treatment for peritoneal mesothelioma. The therapy involves cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC. Peritoneal mesothelioma is cancer of the abdominal lining. It is caused by inhaled or ingested asbestos fibers that travel to the lining of the abdomen. Over time,[…]
Peritoneal Mesothelioma
Why Patients Quit PIPAC for Mesothelioma
PIPAC, or pressurized intraperitoneal aerosol chemotherapy, is showing promising results for mesothelioma, but patients don’t finish all their sessions. This is a problem because the patients then limit the effectiveness of their treatment. Researchers in France decided to figure out why patients are quitting their treatments early. Mesothelioma is a[…]
Cytoreductive Surgery and Chemotherapy Improved for Mesothelioma
Improvements have been made for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This treatment combination is typically performed on people with cancers in the abdominal region. One such cancer is peritoneal mesothelioma. Peritoneal mesothelioma is a cancer of the lining of the abdomen caused by asbestos exposure. Peritoneal mesothelioma is[…]
Cytokine Factories to Treat Pleural and Peritoneal Mesothelioma
A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal[…]
Pleurectomy and Decortication is the Best Option for Bicavity Surgery on Peritoneal Mesothelioma
Patients with thoracic and abdominal mesothelioma can extend survival when they are given aggressive surgery. This news came from a study at Baylor College of Medicine in Houston. When patients are given bicavity cytoreductive surgery, they had a median survival of 58.2 months. The results were published in December in[…]
Timely Treatment for Mesothelioma Could Improve Survival
It is best to treat peritoneal mesothelioma as soon as possible. Waiting to receive treatment could prevent a patient from living longer than possible. Information from a study looking at treatment start times was published in the Journal of Gastrointestinal Surgery in November. Researchers observed patients who either received treatment[…]
STAR-101 Could Make CAR T-Cell Therapy More Effective for Mesothelioma Patients
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for[…]
Allocetra and Cisplatin Combination for Mesothelioma
A new immunotherapy treatment is showing promising results against mesothelioma. The therapy consists of a combination of two drugs: one drug that reprograms macrophages and the other is the chemotherapy cisplatin. Mesothelioma is a cancer that does not respond well to treatment. The best option for patients is a combination[…]
Tool to Measure Asbestos Levels in Tissue has Been Created
A new tool to determine levels of asbestos exposure has been developed. The tool, created by Italian researchers, is known as a Retrospective Exposure Assessment (REA). The tool uses a microscope to determine how much asbestos is in lung tissue. The study wants to compare the actual level of asbestos[…]
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Primary Outcome Measures Determine DLTs and RP2Ds in AMXT 1501 in combination with IV DFMO [ Time Frame: 1 year ] Indicate Number of patients with DLTs in AMXT1501 in combination with IV DFMO in patients with advanced cancer to determine the RP2D within the duration of the dose escalation period of the study[…]
